Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. Canada
  4. Bourse de Toronto
  5. Lumiera Health Inc.
  6. News
  7. Summary
    NHP   CA5502541066


SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Lumiera Health : begins sales of Awaye pain relief cream on Amazon marketplace

08/23/2021 | 08:05am EDT

MONTREAL - Lumiera Health Inc. (TSXV: NHP) (the 'Company' or 'Lumiera '), a company specializing in the development and commercialization of natural health products, is pleased to announce that it has received approval to sell topical products on the Amazon platform and that its Awaye Pain Relief Cream has been sent to Amazon's fulfillment center and is now available for sale to customers across Canada. Awaye provides a new generation of relief from acute and chronic pain by acting on the CB2 receptors of the endocannabinoid system, the body's built in pain and inflammation defense system. Awaye is a unique Health Canada approved topical cream that provides relief from pain through complimentary mechanisms of action not found in any other product currently available on the market. 'Our Amazon presence is an important pillar in executing our e-Commerce strategy' says Carlos Ponce, CEO of Lumiera. 'After the successful launch of Awaye's brand-owned e-Commerce website, the company has been focused on partnering with high traffic e-Commerce platforms to expand our online distribution. We expect that Amazon will be an important sales channel for Lumiera's products.'.

About Lumiera Health

Lumiera specializes in the development and commercialization of consumer products for the natural health industry. The Company sells herbal tonics and natural supplements through its Holizen Laboratories division, with a diverse portfolio including a line of innovative sleep aids. The Company is also developing and commercializing a unique range of products acting on the endocannabinoid system and offering novel solutions for the treatment of acute and chronic pain. A pioneer in innovation of plant-based health solutions, the Lumiera brand is rooted in the core values of science, nature and compassion. Passionate about making people feel better, we deliver trustworthy and scientifically proven solutions that work with the body's own systems.

Forward-looking information Certain statements contained in this press release constitute 'forward-looking information' as such term is defined in applicable Canadian securities legislation. The words 'may', 'would', 'could', 'should', 'potential', 'will', 'seek', 'intend', 'plan', 'anticipate', 'believe', 'estimate', 'expect' and similar expressions indicate such 'forward-looking information' as they relate to Lumiera. All statements other than statements of historical fact may be forward-looking information. Such statements reflect Lumiera' current views and intentions with respect to future events, and current information available to Lumiera, and are subject to certain risks, uncertainties and assumptions. Such risks and uncertainties include, among others, the risk factors included in Lumiera' annual management's discussion and analysis for the year ended November 30, 2020, which is available under the issuer's SEDAR profile at www.sedar.com. Material factors or assumptions were applied in providing forward-looking information. Many factors could cause the actual results, performance or achievements that may be expressed or implied by such forward-looking information to vary from those described herein should one or more of these risks or uncertainties materialize. Should any factor affect Lumiera in an unexpected manner, or should assumptions underlying the forwardlooking information prove incorrect, the actual results or events may differ materially from the results or events predicted. Any such forward-looking information is expressly qualified in its entirety by this cautionary statement. Moreover, Lumiera does not assume responsibility for the accuracy or completeness of such forward-looking information. The forward-looking information included in this press release is made as of the date of this press release and Lumiera undertakes no obligation to publicly update or revise any forward-looking information, other than as required by applicable law.


Lumiera Health Inc.

Simon Castonguay

Interim Chief Financial Officer

T: 514-880-7772

E: scastonguay@lumiera.ca

(C) 2021 Electronic News Publishing, source ENP Newswire

Stocks mentioned in the article
ChangeLast1st jan.
AMAZON.COM, INC. -2.90% 3335.55 Delayed Quote.5.47%
LUMIERA HEALTH INC. 0.00% 0.03 Delayed Quote.-25.00%
All news about LUMIERA HEALTH INC.
10/19LUMIERA HEALTH : new first of its kind pain relief cream, Awaye™, activates the body..
10/08LUMIERA HEALTH : Launches New Direct-to-Consumer Platform, Closes Private Placement
10/08Lumiera Health Announces Launch of Its New Direct-To-Consumer Platform
10/08LUMIERA HEALTH : announces launch of its new Direct-to-Consumer platform
10/08Lumiera Health Inc. announced that it has received CAD 0.55 million in funding from 931..
09/14LUMIERA HEALTH : announces Private Placement Extension
08/23LUMIERA HEALTH : begins sales of Awaye pain relief cream on Amazon marketplace
08/20LUMIERA HEALTH : to Sell Awaye Pain Relief Cream on Amazon Platform
08/20LUMIERA HEALTH : begins sales of Awaye™ pain relief cream on Amazon marketplace
08/20Lumiera Health Begins Sales of Awaye Pain Relief Cream on Amazon Marketplace
More news
Sales 2020 0,50 M 0,41 M 0,41 M
Net income 2020 -1,93 M -1,56 M -1,56 M
Net cash 2020 0,99 M 0,80 M 0,80 M
P/E ratio 2020 -1,90x
Yield 2020 -
Capitalization 5,10 M 4,12 M 4,12 M
EV / Sales 2019 18,8x
EV / Sales 2020 8,71x
Nbr of Employees -
Free-Float 57,0%
Duration : Period :
Lumiera Health Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Managers and Directors
Carlos Ponce Chief Executive Officer
Mario Paradis Chief Financial Officer
Kevin Cole Chairman
Richard Giguere Vice President-Commercial Operations
Sector and Competitors
1st jan.Capi. (M$)
JOHNSON & JOHNSON4.03%430 990
ROCHE HOLDING AG15.15%337 974
NOVO NORDISK A/S58.77%242 392
PFIZER, INC.16.44%241 985